Aziz M. Rangwala

Aziz M. Rangwala


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ALAgatha Lyczek
Agatha Lyczek
BBBenedict-Tilman Berger
Benedict-Tilman Berger
ARAziz M. Rangwala
Aziz M. Rangwala
YPYiTing Paung
YiTing Paung
JTJessica Tom
Jessica Tom
MSMarkus August Seeliger
Markus August Seeliger
Significance: We performed an in-cell screen of imatinib binding against a library of Abl kinase mutants derived from patients with imatinib-resistant chronic myeloid leukemia. The majority of mutations readily bind imatinib, posing the question of how these mutations cause resistance in patients. We identified several kinetic mutants, one of which binds imatinib with wild-type affinity but dissociates considerably faster from the mutant kinase. Using NMR and molecular dynamics, we found that this mutation increases the conformational dynamics of the mutant protein, linking conformational dynamics of the protein to drug dissociation. The results underline the importance of drug dissociation kinetics for drug efficacy and propose a kinetic resistance mechanism that may be targetable by altering drug treatment schedules.

26 September 2022 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
APAlexander A. Peterson
Alexander A. Peterson
ARAziz M. Rangwala
Aziz M. Rangwala
MTManish K. Thakur
Manish K. Thakur
PWPatrick S. Ward
Patrick S. Ward
CHChristie Hung
Christie Hung
DLDavid R. Liu
David R. Liu
Although cyclophilins are attractive targets for probing biology and therapeutic intervention, no subtype-selective cyclophilin inhibitors have been described. We discovered novel cyclophilin inhibitors from the in vitro selection of a DNA-templated library of 256,000 drug-like macrocycles for cyclophilin D (CypD) affinity. Iterated macrocycle engineering guided by ten X-ray co-crystal structures yielded potent and selective inhibitors (half maximal inhibitory concentration (IC50) = 10 nM) that bind the active site of CypD and also make novel interactions with non-conserved residues in the S2 pocket, an adjacent exo-site. The resulting macrocycles inhibit CypD activity with 21- to >10,000-fold selectivity over other cyclophilins and inhibit mitochondrial permeability transition pore opening in isolated mitochondria. We further exploited S2 pocket interactions to develop the first cyclophilin E (CypE)-selective inhibitor, which forms a reversible covalent bond with a CypE S2 pocket lysine, and exhibits 30- to >4,000-fold selectivity over other cyclophilins. These findings reveal a strategy to generate isoform-selective small-molecule cyclophilin modulators, advancing their suitability as targets for biological investigation and therapeutic development.

31 July 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
ALAriel Leyte-Vidal
Ariel Leyte-Vidal
RDRosaAnna DeFilippis
RosaAnna DeFilippis
IOIan R. Outhwaite
Ian R. Outhwaite
IKIsabelle Kwan
Isabelle Kwan
JLJi Young Lee
Ji Young Lee
NSNeil P. Shah
Neil P. Shah

22 January 2022 in Molecular & Cellular Oncology
Verified
Journal Article
Open access
ARAziz M. Rangwala
Aziz M. Rangwala
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
MRMatthew B. Robers
Matthew B. Robers
SKStefan Knapp
Stefan Knapp
MSMarkus August Seeliger
Markus August Seeliger
Imatinib, a selective inhibitor of the breakpoint cluster region (BCR)-ABL kinase, is the poster child for targeted cancer therapeutics. However, its efficacy is limited by resistance mutations. Using a quantitative bioluminescence resonance energy transfer assay in living cells, we identified ABL kinase mutations that could cause imatinib resistance by altering drug residence time.

11 May 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
ARAziz M. Rangwala
Aziz M. Rangwala
VMVictoria Mingione
Victoria Mingione
GGGeorge Georghiou
George Georghiou
MSMarkus August Seeliger
Markus August Seeliger
Phosphorylation facilitates the regulation of all fundamental biological processes, which has triggered extensive research of protein kinases and their roles in human health and disease. In addition to their phosphotransferase activity, certain kinases have evolved to adopt additional catalytic functions, while others have completely lost all catalytic activity. We searched the Universal Protein Resource Knowledgebase (UniProtKB) database for bifunctional protein kinases and focused on kinases that are critical for bacterial and human cellular homeostasis. These kinases engage in diverse functional roles, ranging from environmental sensing and metabolic regulation to immune-host defense and cell cycle control. Herein, we describe their dual catalytic activities and how they contribute to disease pathogenesis.

17 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSukrit Singh
Sukrit Singh
VGVytautas Gapsys
Vytautas Gapsys
MAMatteo Aldeghi
Matteo Aldeghi
DSDavid Schaller
David Schaller
ARAziz M. Rangwala
Aziz M. Rangwala
JCJohn Chodera
John Chodera
Small molecule kinase inhibitors are critical in the modern treatment of cancers, evidenced by the existence of over 80 FDA-approved small-molecule kinase inhibitors. Unfortunately, intrinsic or acquired resistance, often causing therapy discontinuation, is frequently caused by mutations in the kinase therapeutic target. The advent of clinical tumor sequencing has opened additional opportunities for precision oncology to improve patient outcomes by pairing optimal therapies with tumor mutation profiles. However, modern precision oncology efforts are hindered by lack of sufficient biochemical or clinical evidence to classify each mutation as resistant or sensitive to existing inhibitors. Structure-based methods show promising accuracy in retrospective benchmarks at predicting whether a kinase mutation will perturb inhibitor binding, but comparisons are made by pooling disparate experimental measurements across different conditions. We present the first prospective benchmark of structure-based approaches on a blinded dataset of in-cell kinase inhibitor affinities to Abl kinase mutants using a NanoBRET reporter assay. We compare NanoBRET results to structure-based methods and their ability to estimate the impact of mutations on inhibitor binding (measured as ΔΔG). Comparing physics-based simulations, Rosetta, and previous machine learning models, we find that structure-based methods accurately classify kinase mutations as inhibitor-resistant or inhibitor-sensitizing, and each approach has a similar degree of accuracy. We show that physics-based simulations are best suited to estimate ΔΔG of mutations that are distal to the kinase active site. To probe modes of failure, we retrospectively investigate two clinically significant mutations poorly predicted by our methods, T315A and L298F, and find that starting configurations and protonation states significantly alter the accuracy of our predictions. Our experimental and computational measurements provide a benchmark for estimating the impact of mutations on inhibitor binding affinity for future methods and structure-based models. These structure-based methods have potential utility in identifying optimal therapies for tumor-specific mutations, predicting resistance mutations in the absence of clinical data, and identifying potential sensitizing mutations to established inhibitors.